Amgen Can't Block Sandoz Biosimilar At Fed. Circ.
A divided Federal Circuit on Wednesday rejected Amgen Inc.'s bid to block sales of Sandoz Inc.'s biosimilar Zarxio during continued litigation between the companies, clearing the way for the first biosimilar...To view the full article, register now.
Already a subscriber? Click here to view full article